4 reasons why to use levetiracetam Review article
Article Sidebar
Published:
Sep 30, 2018
Keywords:
epilepsy, levetiracetam, effectiveness, safety of a therapy
Main Article Content
Abstract
Levetiracetam belongs to a group of new antiepileptic drugs with a complex mechanism of action. Introduced to the pharmaceutical market in the 1980s, to date it has established its position of an effective and a safe drug. This is supported by the predictable pharmacokinetics of the drug, the lack of drug interactions of clinical significance, the low risk of drug resistance as well as the lack of depressant effect on the central nervous system.
Article Details
How to Cite
Białecka, M. (2018). 4 reasons why to use levetiracetam. Medycyna Faktow (J EBM), 11(3(40), 189-193. https://doi.org/10.24292/01.MF.0318.4
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Kumar A., Kadian R.: Levetiracetam. SourceStatPearls [Internet]. Treasure Island (FL), StatPearls Publishing 2018.
2. Levetiracetam. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US) 2006.
3. Deshpande L.S., Delorenzo R.J.: Mechanisms of levetiracetam in the control of status epilepticus and epilepsy. Front. Neurol. 2014; 5: 11.
4. Gillard M., Chatelain P., Fuks B.: Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. Eur. J. Pharmacol. 2006; 536(1-2): 102-108.
5. Lynch B.A., Lambeng N., Nocka K. et al.: The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. U S A. 2004; 101(26): 9861-9866.
6. Kanner A.M., Ashman E., Gloss D. et al.: Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society Neurology 2018; 91(2): 82-90.
7. Kanner A.M., Ashman E., Gloss D. et al.: Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2018; 91(2): 74-81.
8. Gujjarlamudi H.B.: Polytherapy and drug interactions in elderly. J. Midlife Health 2016; 7(3): 105-107.
9. Białecka M., Sławek J.: Interakcje leków w neurologii. Wyd. 1. Via Medica, Gdańsk 2015.
10. Ramsay R.E., Pryor F.: Epilepsy in the elderly. Neurology 2000; 55: S9. Drugs Aging. 2018. DOI: 10.1007/s40266-018-0562-2 [Epub ahead of print].
11. Anderson G.D., Hakimian S.: Pharmacokinetic Factors to Consider in the Selection of Antiseizure Drugs for Older Patients with Epilepsy. Drugs Aging 2018. [Epub ahead of print].
12. Brockmöller J., Thomsen T., Wittstock M. et al.: Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests. Clin. Pharmacol. Ther. 2005; 77(6): 529-541.
13. Ruiz-Giménez J., Sánchez-Alvarez J.C., Cañadillas-Hidalgo F., Serrano-Castro P.J.; Andalusian Epilepsy Society: Antiepileptic treatment in patients with epilepsy and other comorbidities. Seizure 2010; 19(7): 375-382.
14. Tomson T., Xue H., Battino D.: Major congenital malformations in children of women with epilepsy. Seizure 2015; 28: 46-50.
15. Veroniki A.A., Cogo E., Rios P. et al.: Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes. BMC Med. 2017; 15(1): 95.
16. Mawhinney E., Craig J., Morrow J. et al.: Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology 2013; 80(4): 400-405.
17. Tomson T., Battino D., Bonizzoni E. et al.; EURAP Study Group: Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018; 17(6): 530-538.
18. Jędrzejczak J., Bomba-Opoń D., Jakiel G. et al.: Postępowanie z kobietą z padaczką w okresie rozrodczym. Rekomendacje Polskiego Towarzystwa Epileptologii i Polskiego Towarzystwa Ginekologicznego. Ginekol. Perinatol. Prakt. 2017; 2(3): 108-119.
2. Levetiracetam. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US) 2006.
3. Deshpande L.S., Delorenzo R.J.: Mechanisms of levetiracetam in the control of status epilepticus and epilepsy. Front. Neurol. 2014; 5: 11.
4. Gillard M., Chatelain P., Fuks B.: Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. Eur. J. Pharmacol. 2006; 536(1-2): 102-108.
5. Lynch B.A., Lambeng N., Nocka K. et al.: The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. U S A. 2004; 101(26): 9861-9866.
6. Kanner A.M., Ashman E., Gloss D. et al.: Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society Neurology 2018; 91(2): 82-90.
7. Kanner A.M., Ashman E., Gloss D. et al.: Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2018; 91(2): 74-81.
8. Gujjarlamudi H.B.: Polytherapy and drug interactions in elderly. J. Midlife Health 2016; 7(3): 105-107.
9. Białecka M., Sławek J.: Interakcje leków w neurologii. Wyd. 1. Via Medica, Gdańsk 2015.
10. Ramsay R.E., Pryor F.: Epilepsy in the elderly. Neurology 2000; 55: S9. Drugs Aging. 2018. DOI: 10.1007/s40266-018-0562-2 [Epub ahead of print].
11. Anderson G.D., Hakimian S.: Pharmacokinetic Factors to Consider in the Selection of Antiseizure Drugs for Older Patients with Epilepsy. Drugs Aging 2018. [Epub ahead of print].
12. Brockmöller J., Thomsen T., Wittstock M. et al.: Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests. Clin. Pharmacol. Ther. 2005; 77(6): 529-541.
13. Ruiz-Giménez J., Sánchez-Alvarez J.C., Cañadillas-Hidalgo F., Serrano-Castro P.J.; Andalusian Epilepsy Society: Antiepileptic treatment in patients with epilepsy and other comorbidities. Seizure 2010; 19(7): 375-382.
14. Tomson T., Xue H., Battino D.: Major congenital malformations in children of women with epilepsy. Seizure 2015; 28: 46-50.
15. Veroniki A.A., Cogo E., Rios P. et al.: Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes. BMC Med. 2017; 15(1): 95.
16. Mawhinney E., Craig J., Morrow J. et al.: Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology 2013; 80(4): 400-405.
17. Tomson T., Battino D., Bonizzoni E. et al.; EURAP Study Group: Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018; 17(6): 530-538.
18. Jędrzejczak J., Bomba-Opoń D., Jakiel G. et al.: Postępowanie z kobietą z padaczką w okresie rozrodczym. Rekomendacje Polskiego Towarzystwa Epileptologii i Polskiego Towarzystwa Ginekologicznego. Ginekol. Perinatol. Prakt. 2017; 2(3): 108-119.